UniProt ID | PCH2_HUMAN | |
---|---|---|
UniProt AC | Q15645 | |
Protein Name | Pachytene checkpoint protein 2 homolog | |
Gene Name | TRIP13 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 432 | |
Subcellular Localization | ||
Protein Description | Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. Also required for development of higher-order chromosome structures and is needed for synaptonemal-complex formation. In males, required for efficient synapsis of the sex chromosomes and for sex body formation. Promotes early steps of the DNA double-strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity). Plays a role in mitotic spindle assembly checkpoint (SAC) activation. [PubMed: 28553959] | |
Protein Sequence | MDEAVGDLKQALPCVAESPTVHVEVHQRGSSTAKKEDINLSVRKLLNRHNIVFGDYTWTEFDEPFLTRNVQSVSIIDTELKVKDSQPIDLSACTVALHIFQLNEDGPSSENLEEETENIIAANHWVLPAAEFHGLWDSLVYDVEVKSHLLDYVMTTLLFSDKNVNSNLITWNRVVLLHGPPGTGKTSLCKALAQKLTIRLSSRYRYGQLIEINSHSLFSKWFSESGKLVTKMFQKIQDLIDDKDALVFVLIDEVESLTAARNACRAGTEPSDAIRVVNAVLTQIDQIKRHSNVVILTTSNITEKIDVAFVDRADIKQYIGPPSAAAIFKIYLSCLEELMKCQIIYPRQQLLTLRELEMIGFIENNVSKLSLLLNDISRKSEGLSGRVLRKLPFLAHALYVQAPTVTIEGFLQALSLAVDKQFEERKKLAAYI | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
1 | Acetylation | -------MDEAVGDL -------CCCHHHHH | 10.69 | 22223895 | |
9 | Sumoylation | DEAVGDLKQALPCVA CCHHHHHHHHCHHEE | 37.96 | - | |
18 | Phosphorylation | ALPCVAESPTVHVEV HCHHEECCCEEEEEE | 19.01 | 30266825 | |
20 | Phosphorylation | PCVAESPTVHVEVHQ HHEECCCEEEEEEEE | 32.30 | 30266825 | |
30 | Phosphorylation | VEVHQRGSSTAKKED EEEEECCCCCCCHHH | 27.06 | 29214152 | |
31 | Phosphorylation | EVHQRGSSTAKKEDI EEEECCCCCCCHHHC | 34.90 | 29214152 | |
32 | Phosphorylation | VHQRGSSTAKKEDIN EEECCCCCCCHHHCC | 44.16 | 26055452 | |
34 | Ubiquitination | QRGSSTAKKEDINLS ECCCCCCCHHHCCHH | 57.70 | - | |
35 | Ubiquitination | RGSSTAKKEDINLSV CCCCCCCHHHCCHHH | 59.14 | 29967540 | |
41 | Phosphorylation | KKEDINLSVRKLLNR CHHHCCHHHHHHHHH | 18.52 | 21815630 | |
56 | Phosphorylation | HNIVFGDYTWTEFDE CCCEEECCEECCCCC | 12.45 | 22817900 | |
72 | Phosphorylation | FLTRNVQSVSIIDTE CCCCCCEEEEEEEEE | 17.35 | 29214152 | |
74 | Phosphorylation | TRNVQSVSIIDTELK CCCCEEEEEEEEEEE | 21.05 | 21712546 | |
81 | Ubiquitination | SIIDTELKVKDSQPI EEEEEEEEECCCCCC | 40.79 | 21963094 | |
83 | Ubiquitination | IDTELKVKDSQPIDL EEEEEEECCCCCCCH | 50.50 | 22817900 | |
147 | Phosphorylation | VYDVEVKSHLLDYVM EEEHHHHHHHHHHHH | 25.25 | 20068231 | |
152 | Phosphorylation | VKSHLLDYVMTTLLF HHHHHHHHHHHHHHC | 7.65 | 23898821 | |
155 | Phosphorylation | HLLDYVMTTLLFSDK HHHHHHHHHHHCCCC | 12.30 | 20068231 | |
156 | Phosphorylation | LLDYVMTTLLFSDKN HHHHHHHHHHCCCCC | 11.90 | 23898821 | |
160 | Phosphorylation | VMTTLLFSDKNVNSN HHHHHHCCCCCCCCC | 47.87 | 23898821 | |
183 | Phosphorylation | LLHGPPGTGKTSLCK EECCCCCCCHHHHHH | 41.08 | - | |
185 | Ubiquitination | HGPPGTGKTSLCKAL CCCCCCCHHHHHHHH | 34.48 | 27667366 | |
185 (in isoform 1) | Ubiquitination | - | 34.48 | 21890473 | |
190 | Ubiquitination | TGKTSLCKALAQKLT CCHHHHHHHHHHHHH | 52.29 | 22817900 | |
190 | Acetylation | TGKTSLCKALAQKLT CCHHHHHHHHHHHHH | 52.29 | 27452117 | |
195 | Ubiquitination | LCKALAQKLTIRLSS HHHHHHHHHHHEHHH | 41.83 | 27667366 | |
206 | Phosphorylation | RLSSRYRYGQLIEIN EHHHCCCCCEEEEEC | 10.57 | - | |
216 | Phosphorylation | LIEINSHSLFSKWFS EEEECCHHHHHHHHH | 30.82 | - | |
219 | Phosphorylation | INSHSLFSKWFSESG ECCHHHHHHHHHHHC | 33.98 | 24719451 | |
227 | Acetylation | KWFSESGKLVTKMFQ HHHHHHCHHHHHHHH | 49.41 | 27452117 | |
227 (in isoform 1) | Ubiquitination | - | 49.41 | 21890473 | |
227 | Ubiquitination | KWFSESGKLVTKMFQ HHHHHHCHHHHHHHH | 49.41 | 22817900 | |
231 | Ubiquitination | ESGKLVTKMFQKIQD HHCHHHHHHHHHHHH | 30.18 | 22817900 | |
235 | Ubiquitination | LVTKMFQKIQDLIDD HHHHHHHHHHHHCCC | 30.94 | 29967540 | |
288 (in isoform 1) | Ubiquitination | - | 38.12 | 21890473 | |
288 | Ubiquitination | LTQIDQIKRHSNVVI HHHHHHHHHHCCEEE | 38.12 | 21963094 | |
288 | 2-Hydroxyisobutyrylation | LTQIDQIKRHSNVVI HHHHHHHHHHCCEEE | 38.12 | - | |
291 | Phosphorylation | IDQIKRHSNVVILTT HHHHHHHCCEEEEEC | 35.04 | 30576142 | |
297 | Phosphorylation | HSNVVILTTSNITEK HCCEEEEECCCCCCE | 19.63 | 20860994 | |
298 | Phosphorylation | SNVVILTTSNITEKI CCEEEEECCCCCCEE | 19.14 | 20860994 | |
316 (in isoform 1) | Ubiquitination | - | 37.28 | 21890473 | |
316 | Ubiquitination | FVDRADIKQYIGPPS EECHHHHHHHHCCHH | 37.28 | 21963094 | |
318 | Phosphorylation | DRADIKQYIGPPSAA CHHHHHHHHCCHHHH | 11.66 | 24043423 | |
323 | Phosphorylation | KQYIGPPSAAAIFKI HHHHCCHHHHHHHHH | 33.40 | 20446291 | |
331 | Phosphorylation | AAAIFKIYLSCLEEL HHHHHHHHHHHHHHH | 7.98 | 24043423 | |
333 | Phosphorylation | AIFKIYLSCLEELMK HHHHHHHHHHHHHHC | 10.32 | 24043423 | |
340 | Ubiquitination | SCLEELMKCQIIYPR HHHHHHHCCCCCCCH | 35.30 | 21963094 | |
345 | Phosphorylation | LMKCQIIYPRQQLLT HHCCCCCCCHHHHHH | 8.26 | 24043423 | |
358 | Sulfoxidation | LTLRELEMIGFIENN HHHHHHHHHCCCCCC | 5.92 | 21406390 | |
367 | Phosphorylation | GFIENNVSKLSLLLN CCCCCCHHHHHHHHH | 29.97 | 21712546 | |
370 | Phosphorylation | ENNVSKLSLLLNDIS CCCHHHHHHHHHHHH | 22.25 | 21712546 | |
377 | Phosphorylation | SLLLNDISRKSEGLS HHHHHHHHHCCCCCC | 36.20 | 21406692 | |
380 | Phosphorylation | LNDISRKSEGLSGRV HHHHHHCCCCCCHHH | 35.47 | 20068231 | |
384 | Phosphorylation | SRKSEGLSGRVLRKL HHCCCCCCHHHHHHH | 35.10 | 20068231 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of PCH2_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of PCH2_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PCH2_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND MASSSPECTROMETRY. | |
"Immunoaffinity profiling of tyrosine phosphorylation in cancercells."; Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,Zha X.-M., Polakiewicz R.D., Comb M.J.; Nat. Biotechnol. 23:94-101(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-56, AND MASSSPECTROMETRY. |